Celiac disease (CD) is a disorder of the small intestine caused by intolerance to wheat gluten and related proteins in barley and rye. CD4 + T cells have a central role in CD, recognizing and binding complexes of HLA-DQ2.5 bearing gluten peptides that have survived digestion and that are deamidated by tissue transglutaminase (TG2), propagating a cascade of inflammatory processes that damage and eventually destroy the villous tissue structures of the small intestine. In this study, we present data showing that recombinant DQ2.5-derived molecules bearing covalently tethered 2-gliadin-61-71 peptide have a remarkable ability to block antigen-specific T-cell proliferation and inhibited proinflammatory cytokine secretion in human DQ2.5-restricted 2-gliadin-specific T-cell clones obtained from patients with CD. The results from our in vitro studies suggest that HLA-DQ2.5-derived molecules could significantly inhibit and perhaps reverse the intestinal pathology caused by T-cell-mediated inflammation and the associated production of proinflammatory cytokines.
INTRODUCTION
Celiac disease (CD) is an inflammatory disorder that has a complex genetic etiology involving both innate and adaptive immune responses. 1 -4 Celiac patients do not tolerate gluten, a protein found in wheat, rye, and barley. At the heart of the problem are CD4 + T cells that recognize peptides deamidated by tissue transglutaminase (TG2), facilitating a cascade of inflammatory processes characterized by villus atrophy within the intestinal mucosa, enlarged hyperplastic crypts, and increased intestinal lymphocytes in the lamina propria and epithelium that damage and eventually destroy the villous architecture of the small intestine, interfering with the absorption of nutrients from food. The availability of accurate serological tests have led to the realization that CD is relatively common, affecting 1 of every 120 -300 people in both Europe and North America, and it is estimated that subclinical forms of this disease are even more prevalent. 5 -7 Activation of CD4 + T cells is a multistep process initiated minimally by ligation of antigen (Ag)-specific T-cell receptor (TCR) and CD4 co-receptor with the major histocompatibility complex (MHC) class II / peptide complex present on Agpresenting cells (APCs) (signal 1), and co-stimulation through T-cell surface molecules such as CD28 (signal 2). In studies focused on producing small single-chain MHC mimetics that would retain primary signaling characteristics of the MHC class II heterodimer, we developed a unique class of molecules termed recombinant TCR l igands (RTLs). These molecules were constructed by linking together the MHC class II -1 and -1 domains, with and without covalently linked peptide Ag. 8 Our earliest studies demonstrated that these compounds formed complexes with antigenic peptides that could be used to detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. 9 Studies with CD4 + , DR2-restricted T-cell ARTICLES clones from human patients suffering from multiple sclerosis demonstrated that DR2-derived RTLs altered TCR zeta-chain phosphorylation, induced a short-term sustained mobilization of calcium in T cells, and decreased extracellular signal-regulated kinase activity with concomitant induction of interleukin (IL)-10 production in an Ag-specific manner. 10 Studies using the Lewis rat A1 hybridoma documented that T-cell activation could be directly modulated in vitro by binding of multimeric RT1.B-derived RTLs, inducing early TCR signaling and a unique pattern of downstream activation. 11 The ability of these compounds to tolerize Ag-specific T-cell clones was recently expanded to include the construction of human leukocyte antigen (HLA)-DP2-and DP4-derived RTLs with the ability to tolerize HLA-DP2-restricted beryllium-specific pathogenic T cells. 12 The potential of these molecules for use in the treatment of other human diseases has been expanded from our studies in EAE 8 -12 with tolerization data in animal models including collagen-induced arthritis 13 experimental autoimmune uveitis, 14 and neuroprotection data, modulating T-cell trafficking, in the mid cerebral artery occlusion model of stroke. 15 The broad applicability of this platform technology compelled us to explore its utility in CD. DQ2.5-derived RTLs were designed, a purification scheme was developed, and DQ2.5-derived molecules were biochemically and biophysically characterized. DQ2.5-derived RTLs bearing covalently tethered gluten-derived 2-gliadin-61-71 peptide showed a remarkable ability to block Ag-specific T-cell proliferation and inhibited cytokine production in human DQ2-restricted 2-gliadin-specific intraepithelial lymphocyte T-cell clones obtained from patients with CD.
RESULTS

Construction and characterization of DQ2-derived RTL800 and peptide tethered variants
We have constructed recombinant HLA-DQ2.5 (RTL800 series) using a strategy previously described for constructing other RTLs from MHC class II alleles. 8 -10,12, 16 The primary sequence of " empty " rDQ2.5 (RTL800) aligned with the previously described HLA-DR2-and HLA-DP2-derived RTLs is shown in ( Figure 2a ). The presence of the native conserved disulfide bond between DQB1 * 0201 C15 and C79 was demonstrated by a gel shift assay ( Figure 2a , inset). Similar to the progenitor DR2-derived RTLs, DQ2-derived RTLs tend to form oligomers of 15 -22 molecules ( Figure 2a , and data not shown). In the studies described here, we have used DQ2.5-derived RTL multimers, which as described below, retain potent biological activity. Mutation of DQA1 * 0501 Cysteine 44 to serine reduced the level of intermolecular disulfide cross-linked species in both the " empty " and peptide Ag-coupled RTLs (compare reduced + -ME ( -mercaptoethanol) vs. − -ME, Figure 2a , inset). Authenticity of the purified proteins was further confirmed by N-terminal aminoacid analysis (data not shown). Immunoblot analysis of the purified proteins with DQ2.5-specific monoclonal antibodies (mAb) 2.12.E11 ( Figure 2b ) and Tu39 (data not shown) confirmed the identity of the compounds ( Figure 2b ). Circular dichroism confirmed that the RTLs had highly ordered secondary structures ( Figure 2c ), and comparison with the secondary structures of MHC class II molecules determined by X-ray crystallography provided strong evidence that the RTLs shared the -sheet platform / anti-parallel -helix secondary structure common to all MHC class II Ag-binding domains ( Table 1 ) . 17 -22 
DQ2-derived RTL800 can discriminate between native and TG2-modified a2-gliadin peptides
Peptide binding studies were performed using 2-gliadin-59-78, a peptide that contains all three immunodominant epitopes present in the naturally occurring 2-gliadin-57-89 33-mer that remains intact following digestion with gastric, pancreatic, and brush border membrane proteases ( Figure 3 ). 1 -4 " Empty " DQ2-derived RTL800 can clearly discriminate between the wild-type " QQ " vs. the deamidated forms of the peptide, with the highest apparent affinity for the " EE " doubly deamidated peptide ( Figure 3 ). RTL800 remained stable for the duration of the experiments, as confirmed by commassie staining and western blot analysis (data not shown). RTL800 with captured Figure 1 Primary amino-acid sequence alignment of human DQ2-, DR2-, and DP2-derived recombinant T-cell receptor l igands (RTLs). " Empty " rDQ2.5 (RTL800) was derived from DQ2 (DQA1 * 0501 / DQB1 * 0201), RTL302 from DR2 (DRA1 * 0101 / DRB1 * 1501), and RTL600 from DP2 (DPA1 * 0103 / DPB1 * 0201) primary sequences. Gaps in the sequences for optimal alignment ( * ) and the -1 / / -1 junction ( < | ; ) are shown. The conserved cysteines that form a disulfide bond are boxed, and the cysteine residue present in DQ2-derived RTL800 that has been changed to serine in RTL801 to prevent intermolecular disulfide bond formation and aggregation is underlined. Genes encoding RTL802 and RTL803, variants of 800 and 801, respectively, encode proteins that have the amino-terminal peptide sequence (M FPQPELPYPQP GSGSGSGSGSGSGSGS) instead of the starting methionine. These molecules bear antigenic 2-gliadin-61-71 (Q65E) " -II " peptide and linker (the gliadin-derived sequence is underlined).
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rhodamine-labeled peptide migrates with a higher molecular weight than " empty " RTL800, and the appearance of multiple bands in the rhodamine panel suggests conformational heterogeneity for the population of RTL800 molecules loaded with peptide. Our interpretation is that the faint upper band may represent a proportion of RTL800 loaded with the " EE " peptide that is in a less compact " floppy " conformation, thus hindering its mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), consistent with previous studies using purified full-length MHC class II heterodimers. 23, 24 Preliminary experiments using circular dichroism further suggest that the deamidated " EE " peptide is structurally distinct from the native peptide (data not shown) and these structural features strongly favor efficient and stable binding to DQ2-derived RTL800, supporting previous reported studies using full-length DQ2. 25
HLA-DQ2-derived RTL803 blocked Ag-specific T-cell proliferation
Ag-specific T-cell clones were cultured from small intestinal biopsies of patients with CD. T-cell proliferation and cytokine production were monitored in vitro as surrogate markers for T-cell-mediated inflammation hypothesized to perpetuate intestinal pathology, and we tested the ability of RTLs to modulate T-cell proliferation and cytokine production, and determined the clonal specificity of this inhibition. Our strategy to design and produce DQ2.5-derived RTLs was based on our previous experience, suggesting that these compounds could be used to specifically modulate the population(s) of cells involved in pathology, minimizing the impact on the rest of the immune repertoire. After optimizing our proliferation assay using HLA-DQ2.5 expressing Epstein -Barr virus (EBV)-transformed human B cells as APCs, we compared the proliferation of patient-derived Ag-specific T clones exposed to 10 g ml − 1 of gluten or TG2-treated gluten, or 2 and 10 M gluten-derived peptides p1274 (PQPELPYPQPQLPY), or p1729 (PQTQQPEQPFPQPQ). The proliferative response of clones TCC364.1.0.4 (specific for 2-gliadin 61-71(Q65E) " -II " peptide found in p1274) ( Figure 4a ) and TCC387.19 (specific for the " -VII " peptide p1729) ( Figure 4b ) provided distinctive activation signals that allowed a critical assessment of peptide-specific inhibitory potential of the DQ2.5derived RTL802 molecule bearing the covalently tethered -II peptide. Three copies of the TCC364.1.0.14 -II epitope, minimally consisting of the sequence PQPELPYPQ, are present within the naturally occurring immunodominant 2-gliadin-57-89 33-mer following deamidation by tissue TG2 ( Figure 3 , lower panel). 1 -4 RTL802 carrying the covalently tethered -II epitope potently and specifically blocked proliferation of the cognate -II-specific TCC364.1.0.14 ( Figure 4a ). Importantly, RTL802 did not inhibit proliferation of the non-cognate -VIIspecific TCC387.19 ( Figure 4b ). RTL361, a recombinant DR4 molecule that carries a covalently tethered collagen peptide (AGFKGEQGPKGEP), was developed for treatment of arthritis and has demonstrated efficacy in protecting animals from collagen-induced arthritis. 13 We used this molecule as a control in our studies. RTL361 did not inhibit proliferation of either ) , and gliadin-61-71 covalently tethered RTL802 and 803. Inset, Samples of purified RTLs were boiled for 5 min in Laemmli sample buffer ± the reducing agent -mercaptoethanol ( -ME), and then analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE, 12 % ). Non-reduced RTLs ( − -ME) have a smaller apparent molecular weight than reduced RTLs ( + -ME), indicating the presence of a disulfide bond. First and last lanes show the molecular weight standards albumin (66 kDa), ovalbumin (45 D), carbonic anhydrase (31 kDa), and soybean trypsin inhibitor (21.5 kDa). Note that the molecules with the C44S mutation (RTL801 and 803) have dramatically reduced levels of intermolecular disulfide linked aggregates compared with RTLs 800 and 802 with the wild-type sequence. ( b ) DQ2.5-derived RTLs are recognized by DQ2.5specific monoclonal antibody (mAb) 2.12.E11. Five g DQ2-derived RTL800 and 802, DR4-derived RTL363 as a negative control, 40 or full-length recombinant DQ2 / CLIP as a positive control were blotted in duplicate onto nitrocellulose membranes. Membranes were blocked with 10 % fetal calf serum in phosphate-buffered saline overnight and then incubated with anti-DQ mAbs SPV-L3 (undetermined epitope), 41 2.12.E11 (DQB1 * 0201, 0202 and 0203-specific) 42 and SFR-20 5 (undetermined epitope) 43 for 1 h. Blots were washed 2 × and then secondary antibodies goat-anti-rat horseradish peroxidase (HRP) (SFR-20 5) and rabbitanti-mouse HRP antibodies were used for the detection. Immunoglobulin G were used as the control. All three antibodies recognize full-length DQ2 / CLIP, only mAb 2.12.E11 recognized DQ2-derived RTL800 and RTL802, and none of these antibodies could detect DR4-derived RTL363. Our data are consistent with SPV-L3 and SFR-20 5 recognizing the 2-or 2-domains of full-length DQ2 and mAb 2.12.E11 recognizing a unique epitope present in the DQ2.5-derived RTLs that minimally consists of 1-domain residues G45, E46, and F47. 42 ( c ) Circular dichroism measurements were performed at 25 ° C on an Aviv Model 215 CD spectrometer (Lakewood, NJ) using 0.1 mm cells, at 0.5 nm intervals from 260 to 180 nm. Concentration values for each protein solution were determined by amino-acid analysis. Buffer, 20 m M Tris, pH 8.5. Deconvolution and analysis of the secondary structure presented in Table 1 was performed using the variable selection method. 50 Data are expressed as Delta-epsilon per mole per cm. ARTICLES clone ( Figure 4 ). Thus, inhibition of TCC364.1.0.14 by RTL802 required both the appropriate antigenic peptide and the appropriate HLA-DQ2.5-derived RTL platform.
HLA-DQ2.5-derived RTL802 blocked Ag-specific production of cytokines
Intestinal lymphocytes isolated from active lesions taken from intestinal biopsies of patients with CD show an extraordinarily complex cytokine profile. As well, long-term TCC from CD patient biopsies cultured in vitro maintain a complex cytokine profile. These TCCs showed DQ2.5-restricted proliferation ( Figure 4 ) and cytokine production ( Figure 5 ) to 2-gliadin peptides in culture upon restimulation with gliadin peptide. We have consistently documented that RTL therapy induces Ag-specific cytokine changes in T-cell lines and clones isolated from both humans and rodents. In this study, we demonstrate for the first time that DQ2.5-derived RTL802 blocked Ag-specific cytokine production specifically in cognate T cells. As shown in Figure 5 , both TCC364.1.0.14 { -II p1274 (PQPELPYPQPQLPY) peptide-specific} and TCC387.19 { -VII p1729 (PQTQQPEQPFPQPQ) peptide-specific} produced a wide range of cytokines upon exposure to EBV-transfected DQ2 expressing B cells loaded with TG2-treated gluten or cognate Ag, including IL-2, IL-5, IL-6, IL-10, IL-17, interferon-, and tumor necrosis factor (TNF)-. Pretreatment of TCC364.1.0.14 with RTL802 (10 M ) bearing the cognate -II p1274 peptide inhibited all secreted cytokines significantly, with the most dramatic reduction observed for IL-2 and IL-5 ( ~ 70 % decrease), and TNF-, either when TG2-treated gluten or when the p1274 peptide was used for stimulation ( Figure 5a ). In contrast, RTL802 had no significant effect on cytokine secretion by TCC387.19 that recognizes the -VII p1729 peptide Ag. Moreover, " empty " DQ2-derived RTL800 had no significant effect on either T-cell specificity ( Figure 5 ), nor did DR4-derived RTL363 (data not shown). These studies strongly support the idea that RTL802 can modulate the cognate pathogenic CD-associated CD4 + T cells. Abbreviations: HLA -MHC, human leukocyte antigen -major histocompatibility complex; RTL, recombinant T-cell receptor l igand. a Derived from HLA-MHC class II -1 and -1 domains as indicated. Secondary structure content derived from the deconvoluted spectra of the DQ2-derived RTLs presented in Figure 2 , and published studies, as indicated. Analysis of the secondary structure was performed using the variable selection method, 50 
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DISCUSSION
Experiments presented in this article describe, for the first time, the ability of recombinant single-chain HLA-DQ2.5-derived molecules to modulate the behavior of pathogenic CD4 + T cells isolated from the biopsies of CD patients. Soluble recombinant MHC class II molecules in various forms have been developed, including full-length detergent solubilized MHC class II heterodimers, 26, 27 various forms of the extracellular 1 2 and 1 2 heterodimeric domains, 28 -31 and recently the 1 and 1 domains genetically linked into a single-polypeptide chain. 8 -10,17,32 RTL appears to be the smallest structure that retains the peptide binding / TCR recognition features of MHC class II molecules. 33 Although the ability of HLA-DR2-and HLA-DP2-derived RTLs to modulate T-cell behavior in vitro 11, 32 and in vivo 12,34 -36 has been extensively studied, this is the first study to our knowledge that describes the applicability of RTL therapy toward HLA-DQmediated pathology.
We have constructed recombinant single-chain TCR ligands from HLA-DQ2.5 (RTL800 series) using the same logic as has been described for constructing other RTLs from MHC class II alleles, including human DR-and DPderived 8,10,12 and murine IAs-, IAb and rat RT1.B-derived RTLs. 8, 9, 16 What remains allele-dependent is whether or not the constructs form oligomers. In our previously described protein engineering studies of RTLs derived from HLA-DR2 (DRB1 * 1501 / DRA * 0101), 17 we found that DR2-derived molecules formed multimers, with approximately 10 % of the molecules in the form of stable dimers and the remainder purified in the form of higher-order structures above 300,000 Da. 17 HLA-DP2 molecules, however, are exclusively monomers. 12 One part of the explanation for these observations is that the molecules contain self-binding motifs, with DR2 and DQ2 containing multiple self-binding motifs, whereas DP2 does not contain any (G.G. Burrows, unpublished data). As multimeric and monomeric RTLs retain biological activity, 10,34 we continue to work on methods with the goal of converting these multimeric complexes into monomers with retention of biological activity, as an Food and Drug Administration prerequisite toward eventual use as human therapeutics. In the case of DR2-derived RTLs, 19 proliferates in response to TG2-treated gluten (10 g ml − 1 ) or the -VII p1729 (PQTQQPEQPFPQPQ) peptide (10 g ml − 1 ). Epstein -Barr virus-transformed human B cells expressing HLA-DQ2.5 loaded with antigens were used as antigen-presenting cells (APCs). The T / APC ratio was 1:1, with 60,000 T cells per well. Antigens used included 10 g ml − 1 of gluten, TG2-treated gluten, p1274 (PQPELPYPQPQLPY), or p1729 (PQTQQPEQPFPQPQ) gluten-derived peptides. Data from triplicate wells are presented as average counts per minute ± SD. A representative example of three individual experiments is shown. ARTICLES modification of five sites on the -1 domain was sufficient for engineering monodisperse molecules that retained the ability to bind Ag peptides, inhibit T-cell proliferation in an Agspecific manner and treat EAE in vivo . 37 Although we have identified detergent conditions that will allow us to move forward into clinical trials with the DQ2.5-derived compounds (data not shown), we have not yet succeeded in engineering the DQ2-derived compounds to be monodisperse. This is an active area of investigation in our laboratory, and in the studies described here we have used DQ2-derived RTL multimers, which as shown, retain potent biological activity. Our data presented here demonstrate that TG2-modified gliadin peptides bind to soluble HLA-DQ2.5-derived RTL molecules and that the covalently tethered RTL802 version of this DQ2 / peptide complex blocks Ag-specific T-cell proliferation and cytokine production. As such, these recombinant HLA-DQ2 / peptide molecules represent a powerful new approach toward a therapy for CD.
METHODS
RTLs . General methods for the design, cloning, and expression of RTLs have been described, and HLA-DP2-derived RTL600 was used as template in constructing recombinant HLA-DQ2 genes. 8, 12, 17, 37 Nine pairs of oligo primers specifically designed to modify the template were synthesized and used to generate " empty " rDQ2.5 (RTL800) ( Figure 1 ). Further modifications to the RTL constructs included mutations at various positions toward the purpose of stabilizing monomeric versions of the constructs as described previously for HLA-DR2-derived compounds, 37 and replacement of the cysteine at position 143 (HLA-DQ C 44) with serine, generating RTL801. Genes encoding " empty " rDQ2.5 molecules RTL800 and 801 were modified by adding sequenceencoding 2-gliadin-61-71 peptide (Q65E) (FPQPELPYPQP) with a linker (GSGSGSGSGSGSGSGS) to the 5 Ј end of the genes, encoding peptide-tethered RTL802 and RTL803, respectively. The genes were directionally ligated into pET21d( + ) vector using NCo I and Xho I restriction enzymes (Novagen, Madison, WI) and transformed into Nova blue Escherichia coli host (Novagen) for positive colony selection, and primary sequence of the constructs was confirmed by DNA sequencing. The corrected plasmid constructs were then transformed Figure 5 HLA-DQ2.5-derived RTL802 significantly attenuates antigen-specific cytokine production. Aliquots of supernatants harvested from the recombinant T-cell receptor l igand (RTL) proliferation assay at 48 h after culture with antigen-presenting cells was used for cytokine analysis. A customized human Bio-Plex cytokine kit was used to detect interleukin (IL)-2, IL-5, IL-6, IL-10, IL-17, interferon (IFN)-, and tumor necrosis factor (TNF)-from TCC364.1.0.14 (panel a) and TCC287.19 (panel b). Each data point represented triplicate samples from each treatment group. Significance between the control and treatment groups was determined by Student ' s t -test. A P -value of < 0.05 was considered statistically significant.
ARTICLES into E. coli strain BL21(DE3) expression host (Novagen). Expression, purification, and refolding of these proteins followed procedures described previously. 35 In brief, BL21(DE3) cells containing the plasmid construct of interest were grown in 1-liter cultures to mid-logarithmic phase (OD 600 = 0.6 -0.8) in Luria-Bertani broth containing carbenicillin (50 mg ml − 1 ) at 37 ° C. Recombinant protein production was induced by addition of 0.5 m M isopropyl -D -thiogalactoside. After incubation for 3 h, the cells were harvested by centrifugation and stored at − 80 ° C before processing. All subsequent manipulations of the cells were at 4 ° C. The cell pellets were resuspended in ice-cold phosphate-buffered saline (PBS), pH 7.4, and sonicated for 4 × 20 s with the cell suspension cooled in a salt / ice / water bath. The cell suspension was then centrifuged, the supernatant fraction poured off, and the cell pellet Circular dichroism measurements . Circular dichroism (CD) spectra were recorded on a JASCO (Easton, MD) J-500A spectropolarimeter with an IF-500 digital interface and thermostatically controlled quartz cells (Hellma, Mulheim, Germany) of 2-, 1-, 0.5-, 0.1-, and 0.05-mm path length depending on peptide and protein concentration. Data are presented as mean residue weight ellipticities. Calibration was regularly performed with (1)-10-camphorsulfonic acid (Sigma, St Louis, MO) to molar ellipticities of 7,780 and 216,160 degree cm 2 , dmol − 1 at 290.5 and 192.5 nm, respectively. 38 In general, spectra were the average of 4 -5 scans from 260 to 180 nm, recorded at a scanning rate of 5 nm min − 1 with a 4-s time constant. Data were collected at 0.1-nm intervals. Spectra were averaged and smoothed using the built-in algorithms of the Jasco program, and buffer base lines were subtracted. Secondary structure was estimated with the program CONTIN. 39 Immunoblot analysis . Western and dot blot analysis ( Figure 2 ) were performed to confirm integrity and identity of the RTL constructs. For dot blot analysis, 5 g DQ2.5-derived RTL800 and 802, DR4-derived RTL363 as a negative control, 40 or full-length recombinant DQ2 / CLIP as a positive control were blotted in duplicate onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with 10 % fetal calf serum in PBS overnight and then incubated with anti-DQ mAbs SPV-L3, 41 2.12. E11 (DQB1 * 0201, 0202, and 0203-specific), 42 and SFR-20 5 (diluted in 1:1,000) 43 for 1 h. Blots were washed 2 × and then secondary antibodies goat-anti-rat horseradish peroxidase (SFR-20 5; diluted 1:5,000) and rabbit-anti-mouse horseradish peroxidase antibodies (diluted in 1:5,000) were used for detection. Immunoglobulin G was used as the control (dot blot was a kind gift of Stig Tollefsen and Ludvig M Sollid at the Centre for Immune Regulation, Institute of Immunology, University of Oslo and Rikshospitalet University Hospital, Oslo, Norway, Stig.Tollefsen@ rr-research.no ). All three antibodies recognize full-length DQ2 / CLIP, only mAb 2.12.E11 recognized DQ2-derived RTL800 and RTL802, and none of these antibodies could detect DR4-derived RTL363. For western blot analysis, SDS-PAGE separated proteins were transferred to PVDF membranes for 1 h at room temperature. Membranes were blocked with 3 % bovine serum albumin in PBS / 0.05 % Tween 20 and probed with mAb Tu39-FITC (BD Biosciences, San Jose, CA). Tu39 is a mouse IgG2a antibody that recognizes an epitope conserved on all human HLA class II molecules. 44, 45 PVDF membranes were scanned for fluorescein isothiocyanate-cojugated Tu39 using a BioRad (Hercules, CA) Molecular Imager FX.
Peptide binding assay . A peptide capture method was used to characterize peptide binding to the RTLs. In brief, 400 pmol (10 g) of protein were mixed with 4 nmol of amino-terminal rhodamine-labeled peptides (Genscript, Piscataway, NJ) in a total volume of 60 l buffer (100 m M phosphate buffer at pH 6 containing 0.01 % sodium azide, 1 m M EDTA and 0.05 % SDS) and incubated at 37 ° C for 60 h. The reactions were stopped by adding one volume (60 l) of 1.5 M Tris, 0.1 % SDS, and 20 % glycerol pH 8.8 and placed on ice for 1 -2 h. The capture mixture (40 l containing 2.5 g RTL) was analyzed by SDS-PAGE using 10 -20 % gradient Tris-tricine pre-cast peptide gels (Cat no. 345-0067, Bio-Rad). Following separation, gels were scanned for rhodamine at 580 nm using a BioRad Molecular Imager FX to monitor peptide capture. Pre-stained molecular weight markers (Page-ruler prestained protein ladder (Cat no. SM0671, Fermentas, Burlington, Ontario, Canada) were used to track location of captured peptides on gels.
RTL inhibition of proliferation assay .
A T-cell proliferation assay described previously 37, 46, 47 was used as an RTL function assay.
(T-cell proliferation assays were performed by Stig Tollefsen in Ludvig Sollid ' s Laboratory at the Centre for Immune Regulation, Institute of Immunology, University of Oslo and Rikshospitalet University Hospital, Oslo, Norway.) In brief, 6 × 10 5 gliadin-specific T cells derived from patients with CD were pre-incubated with 4 or 8 M of DQ2.5derived RTLs, DR4-derived RTL361 (negative control), or buffer alone for 48 h, and then washed twice with culture medium to remove RTLs. Approximately 6 × 10 5 irradiated (7500 rad) EBV-transformed DQ2 expressing B cells (Clone, STEIINLIN, ECACC, Salisbury, GB) were precultured with various gliadin Ags at 2 or 10 M concentration for 20 h in U-bottom 96-well plate. Ags tested included 10 g ml − 1 TG2-treated gluten, 2 and 10 M gliadin peptide p1274 (PQPELPYPQPQLPY), which contains the minimal -II peptide (PQPELPYPQ), and 10 M -VII gliadin peptide p1729 (PQTQQPEQPFPQPQ). 48 Ags used in the experiments were prepared as described previously. 46, 49 Briefly, the 100 M native gluten Ags were pre-incubated with 150 g ml − 1 human recombinant TG2 in 100 m M Tris (pH 7.4) with 2 m M CaCl 2 for 2 h at 37 ° C. The synthetic peptides were prepared by solid-phase peptide synthesis on a robotic system (Syro MultiSynTech, Bochum, Germany) using Fmoc / O-t-butyl chemistry. Identity of the peptides was confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, and purity was analyzed by reversed-phase high-performance liquid chromatography. T cells were mixed with B cells in the presence of Ags (1:1 ratio) and incubated for 48 h. T-cell proliferation was measured by the uptake of [ 3 H]-thymidine (1 Ci [ 3 H]-thymidine per well) that was added in the final 16 h, and supernatants (50 l) were collected before adding [ 3 H]-thymidine for cytokine analysis. Each treatment was performed in triplicate. Data are representative of three independent experiments.
Detection and quantification of cytokine production using Bio-Plex cytokine assays . Aliquots of supernatants harvested from the RTL proliferation assay at 48 h after culture with APCs was used for cytokine analysis. A customized human Bio-Plex cytokine kit (Luminex, Austin, TX) was used to detect IL-2, IL-5, IL-6, IL-10, IL-17, interferon-, and TNF-ARTICLES simultaneously, as described by the manufacturer ' protocol ( http://www. bio-rad.com/BioPlexSystem/ ). Data were collected on a Luminex 200 (Bio-Rad), and the data were analyzed using Bio-Plex Management software. Each data point represented triplicate samples from each treatment group. Significance between the control and treatment groups was determined by Student ' s t test. A P -value of < 0.05 was considered statistically significant.
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